Hibino Y, Fujisawa S, Fujimaki K, Hagihara M, et al. Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice. Leuk Res 2025;152:107689.
PMID: 40203479